ClinicalTrials.gg
Not yet recruitingNCT07503340Operetta IIIUpdated Oct 14, 2026

A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

A Phase 2 interventional study of Ocrelizumab co-formulated with rHuPH20 in Relapsing-remitting Multiple Sclerosis, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Oct 14, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche — 2 open to participants now, 5 under way, 2 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Hoffmann-La Roche.

Planned enrollment
11th of 11
25 · median 188
Started
2026
with 1 other
Phase 2
3 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2, and was the 12th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

2 of the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to \<18 years with RRMS. The study consists of a 48-week treatment period, an Optional Ocrelizumab Extension (OOE) period of at least 48 weeks, and Safety Follow-up (SFU) for 104 weeks.

Read the detailed description

For participants who are under 18 years old at the end of the OOE period, it may be extended until the participant turns 18 years old (or as required per local regulation) or until commercial ocrelizumab is approved for children and adolescents and available in the country for these participants, whichever occurs first.

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents from 10 years to less than 18 years of age, at the time of baseline visit
  • Body weight ≥25 kg
  • Diagnosis of RRMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, or McDonald criteria 2017 or 2024
  • Neurologic stability for at least 30 days prior to screening, and between screening and baseline
  • Expanded Disability Status Scale (EDSS) score, 0-5.5, at screening
  • Must have received all childhood required vaccinations as per local/national recommendations for childhood vaccination against infectious diseases

Exclusion criteria

Exclusion Criteria:

  • Participants who are positive for aquaporin 4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) antibody are not eligible to participate in the study
  • Any known presence or suspicion of other neurologic disorders that may mimic multiple sclerosis (MS)
  • Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit
  • History or known presence of recurrent or chronic infection (e.g., [HIV], syphilis, tuberculosis [TB])
  • against SC injections or other conditions not suitable for SC injections, e.g., extremely thin SC fat layer
  • History of a severe allergic or anaphylactic reaction to humanized or murine monoclonal antibody or known to any component of ocrelizumab solution
  • Contraindications to mandatory premedications (i.e., and histamines), including closed-angle glaucoma for antihistamines
  • Participants who have previously received treatment with B cell-targeted therapies, including ocrelizumab
  • Any previous treatment with cyclophosphamide, alemtuzumab, anti-CD4, cladribine, mitoxantrone, daclizumab, laquinimod, total body irradiation, or bone marrow transplantation
  • Treatment with any agent within 24 weeks of screening or 5 half-lives, whichever is longer (or longer if indicated by the PD action of the drug)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Ocrelizumab

    Participants will receive ocrelizumab co-formulated with recombinant human hyaluronidase (rHuPH20), 480 milligrams (mg) (body weight \<35 kilograms \[kg\]) or 920 mg (body weight ≥35 kg), as a SC injection, every 6 months during the 48-week treatment and OOE periods.

    Drug: Ocrelizumab co-formulated with rHuPH20

Interventions

  • DrugOcrelizumab co-formulated with rHuPH20

    Ocrelizumab co-formulated with rHuPH20 will be administered as per the schedule specified in the arm.

    Also known as: RO4964913; Ocrevus

06

What researchers measure

Primary outcomes

  1. Peak Concentration (Cmax) of Ocrelizumab After the First SC Injection

    Time frame: Up to 24 weeks

  2. Area Under the Concentration-time Curve Over a Dosing Interval (AUCtau) After the First SC Injection of Ocrelizumab

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Incidence and Nature of Adverse Events (AEs)

    Time frame: Minimum of 200 weeks

  2. Percentage of Participants Who Discontinued Study Treatment due to AEs

    Time frame: Up to 96 weeks

  3. Levels of Cluster of Differentiation 19+ (CD19+) B-cell Count in Blood

    Time frame: Minimum of 200 weeks

  4. Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab

    Time frame: Minimum of 200 weeks

  5. Number of Participants With ADAs to rHuPH20

    Time frame: Minimum of 200 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2029, 34 months later.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 34 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2031 → Jul 2032, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Jul 30, 2032was Aug 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2029→Aug 31, 2029
Oct 14, 2026
Study completion
Aug 1, 2031→Jul 30, 2032
Oct 14, 2026
Eligibility
1 exclusion criterion edited, 1 added
What changed in the criteria
Exclusion criteria
  • AddedAny known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit
  • EditedAny previous treatment with cyclophosphamide, alemtuzumab, anti-CD4, cladribine, mitoxantrone, daclizumab, laquinimod, total body irradiation, or bone marrow transplantation
Oct 14, 2026
Secondary outcomes
4 time frame changed
What changed in the outcomes
  • Time frameIncidence and Nature of Adverse Events (AEs)Up to 260 weeks → Minimum of 200 weeks
  • Time frameLevels of Cluster of Differentiation 19+ (CD19+) B-cell Count in BloodUp to 260 weeks → Minimum of 200 weeks
  • Time frameNumber of Participants With Anti-drug Antibodies (ADAs) to OcrelizumabUp to 260 weeks → Minimum of 200 weeks
  • Time frameNumber of Participants With ADAs to rHuPH20Up to 260 weeks → Minimum of 200 weeks
Oct 14, 2026
Design
Phase 3→Phase 2
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Aug 1, 2029→Aug 31, 2029
    Study completion Aug 1, 2031→Jul 30, 2032
    Eligibility 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • AddedAny known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit
    • EditedAny previous treatment with cyclophosphamide, alemtuzumab, anti-CD4, cladribine, mitoxantrone, daclizumab, laquinimod, total body irradiation, or bone marrow transplantation
    Secondary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameIncidence and Nature of Adverse Events (AEs)Up to 260 weeks → Minimum of 200 weeks
    • Time frameLevels of Cluster of Differentiation 19+ (CD19+) B-cell Count in BloodUp to 260 weeks → Minimum of 200 weeks
    • Time frameNumber of Participants With Anti-drug Antibodies (ADAs) to OcrelizumabUp to 260 weeks → Minimum of 200 weeks
    • Time frameNumber of Participants With ADAs to rHuPH20Up to 260 weeks → Minimum of 200 weeks
    Design Phase 3→Phase 2
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07503340
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Jul 30, 2032 (estimated)
Last update
Oct 14, 2026

Study contacts

Reference Study ID Number: BA45841 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion